Exchange Traded Concepts LLC Reduces Stock Position in Collegium Pharmaceutical, Inc. $COLL

Exchange Traded Concepts LLC trimmed its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 67.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,067 shares of the specialty pharmaceutical company’s stock after selling 44,065 shares during the period. Exchange Traded Concepts LLC’s holdings in Collegium Pharmaceutical were worth $737,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Amundi boosted its position in shares of Collegium Pharmaceutical by 302.1% in the 1st quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company’s stock worth $1,816,000 after buying an additional 47,024 shares in the last quarter. Bank of New York Mellon Corp raised its position in Collegium Pharmaceutical by 3.1% during the second quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company’s stock worth $7,389,000 after acquiring an additional 7,614 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Collegium Pharmaceutical by 90.5% in the third quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock valued at $6,844,000 after purchasing an additional 92,898 shares in the last quarter. Fortis Capital Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at approximately $408,000. Finally, Rhumbline Advisers increased its stake in shares of Collegium Pharmaceutical by 3.1% during the 1st quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company’s stock worth $3,332,000 after purchasing an additional 3,400 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barclays assumed coverage on Collegium Pharmaceutical in a report on Monday, December 8th. They set an “overweight” rating and a $58.00 target price on the stock. HC Wainwright increased their price objective on Collegium Pharmaceutical from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Truist Financial lifted their price objective on Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $47.00.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $49.48 on Tuesday. The stock has a fifty day moving average price of $44.22 and a 200 day moving average price of $37.54. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $50.79. The firm has a market capitalization of $1.56 billion, a P/E ratio of 30.73 and a beta of 0.61. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $135.55 million for the quarter. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares in the company, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 51,250 shares of company stock worth $2,235,352. 2.51% of the stock is owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.